1. Genipin Attenuates Tau Phosphorylation and Aβ Levels in Cellular Models of Alzheimer’s Disease
- Author
-
Xu Xu, Hui Li, Li Meiting, Weishan Fang, Lijun Yao, Yan Wu, Zhangli Hu, Gu Liang, Hong Xu, Zhijian Lin, Decheng Bi, and Nan Cai
- Subjects
0301 basic medicine ,biology ,Amyloid beta ,Cyclin-dependent kinase 5 ,Tau protein ,Autophagy ,Neuroscience (miscellaneous) ,Gardenia jasminoides ,biology.organism_classification ,In vitro ,Cell biology ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,030104 developmental biology ,0302 clinical medicine ,Neurology ,chemistry ,mental disorders ,Genipin ,biology.protein ,Signal transduction ,030217 neurology & neurosurgery - Abstract
Alzheimer's disease (AD) is a devastating brain disorder characterized by neurofibrillary tangles and amyloid plaques. Inhibiting Tau protein and amyloid-beta (Aβ) production or removing these molecules is considered potential therapeutic strategies for AD. Genipin is an aglycone and is isolated from the extract of Gardenia jasminoides Ellis fruit. In this study, the effect and molecular mechanisms of genipin on the inhibition of Tau aggregation and Aβ generation were investigated. The results showed that genipin bound to Tau and protected against heparin-induced Tau fibril formation. Moreover, genipin suppressed Tau phosphorylation probably by downregulating the expression of CDK5 and GSK-3β, and activated mTOR-dependent autophagy via the SIRT1/LKB1/AMPK signaling pathway in Tau-overexpressing cells. In addition, genipin decreased Aβ production by inhibiting BACE1 expression through the PERK/eIF2α signaling pathway in N2a/SweAPP cells. These data indicated that genipin could effectively lead to a significant reduction of phosphorylated Tau level and Aβ generation in vitro, suggesting that genipin might be developed into an effective therapeutic complement or a potential nutraceutical for preventing AD.
- Published
- 2021
- Full Text
- View/download PDF